imiquimod has been researched along with Carcinoma, Transitional Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA | 1 |
| Arentsen, HC; Cornel, EB; de Reijke, TM; Falke, J; Lammers, RJ; Pozzi, R; Ravic, M; Vergunst, H; Witjes, JA | 1 |
1 trial(s) available for imiquimod and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Age Factors; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Transitional Cell; Cystoscopy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imiquimod; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Patient Safety; Prospective Studies; Risk Assessment; Sex Factors; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
1 other study(ies) available for imiquimod and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Topics: Adenine; Adjuvants, Immunologic; Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Disease Models, Animal; Glycerophospholipids; Imiquimod; Immunologic Factors; Rats; Rats, Inbred F344; Toll-Like Receptor 7; Urinary Bladder; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |